Metallofullerene-based nanoplatform for brain tumor brachytherapy and longitudinal imaging in a murine orthotopic xenograft model

Radiology

Volumn 261, Issue 1, 2011, Pages 136-143

  Shultz, Michael D ^a   Wilson, John D ^a   Fuller, Christine E ^a   Zhang, Jianyuan ^b   Dorn, Harry C ^b   Fatouros, Panos P ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FULLERENE DERIVATIVE; GADODIAMIDE; GADOLINIUM METALLOFULLERENE; GADOLINIUM METALLOFULLERENE 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID LU 177; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRACHYTHERAPY; CANCER CELL CULTURE; CANCER SURVIVAL; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG RETENTION; DRUG SYNTHESIS; DRUG TISSUE LEVEL; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SURVIVAL TIME; TISSUE DISTRIBUTION; TUMOR XENOGRAFT;

ANIMALS; BRACHYTHERAPY; BRAIN NEOPLASMS; COORDINATION COMPLEXES; DISEASE MODELS, ANIMAL; FEMALE; FULLERENES; GLIOBLASTOMA; HETEROCYCLIC COMPOUNDS, 1-RING; LUTETIUM; MICE; MICE, NUDE; NANOTECHNOLOGY; NEOPLASM TRANSPLANTATION; RADIOISOTOPES;

EID: 80053078149     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.11102569     Document Type: Article

References (26)

1. -60: Buckminsterfullerene. Nature 1985;318:162-163.
2. Bethune DS, Johnson RD, Salem JR, Devries MS, Yannoni CS. Atoms in carbon cages: the structure and properties of endohedral fullerenes. Nature 1993;366:123-128.
3. Stevenson S, Rice G, Glass T, et al. Small-bandgap endohedral metallofullerenes in high yield and purity. Nature 1999;401:55-57.
4. Shultz MD, Duchamp JC, Wilson JD, et al. Encapsulation of a radiolabeled cluster inside a fullerene cage, (177)Lu(x)Lu((3-x)) N@C(80): an interleukin-13-conjugated radiolabeled metallofullerene platform. J Am Chem Soc 2010;132(14):4980-4981.
5. Diederich F, Thilgen C. Covalent fullerene chemistry. Science 1996;271(5247):317-323. (Pubitemid 126554870)
6. Thompson BC, Fréchet JM. Polymer-fullerene composite solar cells. Angew Chem Int Ed 2008;47(1):58-77.
7. Li Y, Zhang X, Li Q, Li W. Radioiodination of C60 derivative C60(OH)xOy. J Radioanal Nucl Chem 2001;250(2):363-364.
8. Wharton T, Wilson LJ. Toward fullerene-based x-ray contrast agents: design and synthesis of non-ionic, highly-iodinated derivatives of C60. Tetrahedron Lett 2002;43(4):561-564. (Pubitemid 34085013)
9. Fatouros PP, Corwin FD, Chen Z-J, et al. In vitro and in vivo imaging studies of a new endohedral metallofullerene nanoparticle. Radiology 2006;240(3):756-764. (Pubitemid 44267332)
10. Shu C, Corwin FD, Zhang J, et al. Facile preparation of a new gadofullerene-based magnetic resonance imaging contrast agent with high 1H relaxivity. Bioconjug Chem 2009;20(6):1186-1193.
11. Chawla P, Chawla V, Maheshwari R, Saraf SA, Saraf SK. Fullerenes: from carbon to nanomedicine. Mini Rev Med Chem 2010;10(8):662-677.
12. Partha R, Conyers JL. Biomedical applications of functionalized fullerene-based nanomaterials. Int J Nanomedicine 2009;4:261-275.
13. Bidros DS, Vogelbaum MA. Novel drug delivery strategies in neuro-oncology. Neurotherapeutics 2009;6(3):539-546.
14. Pasha S, Gupta K. Various drug delivery approaches to the central nervous system. Expert Opin Drug Deliv 2010;7(1):113-135.
15. Quant EC, Drappatz J, Wen PY, Norden AD. Recurrent high-grade glioma. Curr Treat Options Neurol 2010;12(4):321-333.
16. Grossman SA, Ye XB, Piantadosi S, et al. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin Cancer Res 2010;16(8):2443-2449.
17. Butowski NA, Sneed PK, Chang SM. Diagnosis and treatment of recurrent high-grade astrocytoma. J Clin Oncol 2006;24(8):1273-1280. (Pubitemid 46622030)
18. Allard E, Passirani C, Benoit JP. Convection-enhanced delivery of nanocarriers for the treatment of brain tumors. Biomaterials 2009;30(12):2302-2318.
19. Vogelbaum MA. Convection enhanced delivery for the treatment of malignant gliomas: symposium review. J Neurooncol 2005;73(1):57-69. (Pubitemid 40823269)
20. Bolskar RD. Gadofullerene MRI contrast agents. Nanomedicine (Lond) 2008;3(2):201-213. (Pubitemid 351611856)
21. Weigle JP, Broome DR. Nephrogenic systemic fibrosis: chronic imaging findings and review of the medical literature. Skeletal Radiol 2008;37(5):457-464.
22. Frenzel T, Lengsfeld P, Schirmer H, Hütter J, Weinmann HJ. Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C. Invest Radiol 2008;43(12):817-828.
23. Perry A, Schmidt RE. Cancer therapy-associated CNS neuropathology: an update and review of the literature. Acta Neuropathol (Berl) 2006;111(3):197-212.
24. Allard E, Hindre F, Passirani C, et al. 188Re-loaded lipid nanocapsules as a promising radiopharmaceutical carrier for internal radiotherapy of malignant gliomas. Eur J Nucl Med Mol Imaging 2008;35(10):1838-1846.
25. Meng H, Gengmei X, Sun B, et al. Potent angiogenesis inhibition by the particulate form of fullerene derivatives. ACS Nano 2010;4(5):2773-2783.
26. Giannini C, Sarkaria JN, Saito A, et al. Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro Oncol 2005;7(2):164-176. (Pubitemid 40590516)